Beyfortus

Indicated For

RSV lower respiratory tract disease prevention in neonates and infants

About This Medication

# Sanofi Patient Connection Patient Guide: How to Get Beyfortus (nirsevimab-alip) at Low or No Cost Beyfortus (nirsevimab-alip) is a long-acting monoclonal antibody that helps protect newborns, infants, and young children from serious lung disease caused by Respiratory Syncytial Virus (RSV).[2][10] Through the **Sanofi Patient Connection** program, eligible families can receive this prescription medication **at no cost** if they meet specific income and other requirements.[1][6] ## About Beyfortus and Why It Matters **Beyfortus** is not a traditional vaccine—it's a single-dose injection given during RSV season to provide rapid protection for up to five months, matching the typical length of RSV season in the US.[5][8] It's indicated for: - Newborns and babies under 1 year entering their first RSV season. - Children up to 24 months old who remain at risk through their second RSV season.[2][4][10] RSV is a common virus that can cause severe lower respiratory tract disease (LRTD) in infants, leading to hospitalization. Clinical studies show Beyfortus reduces RSV-related hospitalizations by up to 83% in the first season and provides benefits into the second season.[5][9] For children after cardiac surgery or those needing a second dose, an additional injection may be recommended.[8] Most families access Beyfortus through private insurance or federal programs like **Vaccines for Children (VFC)** at little to no cost.[2] But if you're uninsured or underinsured, **Sanofi Patient Connection** bridges the gap by providing the medication free to those who qualify.[1] ## Who Qualifies for Sanofi Patient Connection? To get Beyfortus at no cost through this program, you must meet **all** these criteria:[1][6] - Be a resident of the US or US territories. - Be under the care of a licensed US healthcare provider (HCP) who can prescribe and dispense Beyfortus. - Have household income at or below **400% of the Federal Poverty Level (FPL)**. - Lack sufficient insurance coverage (program excludes those with adequate private insurance; Medicaid applicants need denial proof). **Important note**: If your child qualifies for VFC (e.g., no private insurance), use that program first—it's federal and provides Beyfortus free to eligible kids.[2][3] Sanofi Patient Connection is for those who don't qualify for VFC or other government aid. ## Income Eligibility Breakdown Eligibility is based on **annual household income ≤400% FPL**. Use the table below for 2026 guidelines (FPL updates annually; check current levels at the program site). Add $5,380 per additional household member beyond the base.[1] | Household Size | Max Annual Income (400% FPL) | |----------------|------------------------------| | 1 (Individual) | $60,320 | | 2 (Couple) | $81,760 | | 3 | $103,200 | | 4 | $124,640 | | +1 Member | +$21,280 | *Example*: A family of 3 with income under $103,200 may qualify. Provide proof like tax returns or pay stubs.[1][6] The program verifies income strictly—no exceptions noted. ## Insurance Requirements - **No or inadequate insurance**: You must be uninsured or have coverage that doesn't pay for Beyfortus.[1] - **Medicaid/Medicare**: If potentially eligible for Medicaid, submit a denial letter. Medicare patients typically don't qualify as the program targets uninsured/underinsured.[1][6] - **Private insurance**: If you have it, check coverage first—most plans cover Beyfortus with low/no copay.[2] VFC is for uninsured/American Indian/Alaska Native kids, Medicaid-enrolled, or those with no insurance buying power.[2] ## Step-by-Step Application Process 1. **Talk to your doctor**: Get a prescription for Beyfortus and discuss if your child qualifies (e.g., first/second RSV season).[4] 2. **Check VFC first**: Contact your pediatrician or state VFC program if uninsured.[2][3] 3. **Download/Request Application**: Get the form from sanofipatientconnection.com or call the program.[1][6] 4. **Complete the Form**: Include patient details, HCP info, income proof, and insurance status. Your doctor must sign.[6] 5. **Gather Documents**: See below for required items.[1] 6. **Submit**: Mail, fax, or upload per instructions on the form. No online portal specified.[6] 7. **Wait for Approval**: Program reviews within weeks (see FAQ for timeline).[1] **Required Documents** (typically):[1][6] - Proof of income (W-2, tax return, pay stubs). - Proof of residency (utility bill). - Medicaid denial (if applicable). - Prescription and HCP statement. - Insurance cards/denial (if any coverage). ## Timeline and Delivery Processing takes 2-4 weeks after submission, though urgent cases may be faster.[1] Once approved, Beyfortus ships directly to your doctor's office or pharmacy for administration—**not home delivery**.[1][6] It's a one-time dose per season, timed for RSV peak (e.g., fall/winter).[5] For second-season kids or post-surgery, reapply if needed.[8] ## Alternatives if Denied or Ineligible - **VFC Program**: Free for eligible uninsured/Medicaid kids—ask your provider.[2][3] - **Private Insurance**: Most cover Beyfortus; use cost estimator tools.[2] - **Manufacturer Reservations**: Providers can reserve doses via Sanofi's program.[3] - **State Assistance**: Check local health departments for RSV prevention aid. - **Other Sanofi Programs**: Explore Sanofi Cares for additional support.[1] - **Financial Aid Orgs**: Groups like NeedyMeds or PAN Foundation may help. If denied, reapply with updated docs or appeal with more income proof.[1] ## Important Disclaimer This guide is for informational purposes only and based on available program details as of 2026.[1][2] Eligibility rules, FPL levels, and availability can change—**always verify directly with Sanofi Patient Connection** at sanofipatientconnection.com or by phone.[1][6] Not legal/medical advice. Consult your healthcare provider for personalized guidance. Sanofi may update offerings; Beyfortus requires prescription and HCP administration. Program excludes fees from third-party helpers.[6] Word count: 1028.

Program information last verified: March 30, 2026